During the last three months, 5 analysts shared their evaluations of Enovis ENOV, revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 1 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Insights from analysts’ 12-month price targets are revealed, presenting an average target of $72.2, a high estimate of $75.00, and a low estimate of $70.00. Marking an increase of 9.94%, the current average surpasses the previous average price target of $65.67.
Analyzing Analyst Ratings: A Detailed Breakdown
In examining recent analyst actions, we gain insights into how financial experts perceive Enovis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| George Sellers | Stephens & Co. | Announces | Overweight | $72.00 | – |
| Danielle Antalffy | UBS | Announces | Buy | $75.00 | – |
| Mike Matson | Needham | Raises | Buy | $73.00 | $70.00 |
| Kyle Rose | Canaccord Genuity | Raises | Buy | $71.00 | $65.00 |
| Mike Matson | Needham | Raises | Buy | $70.00 | $62.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they ‘Maintain’, ‘Raise’ or ‘Lower’ their stance, it reflects their reaction to recent developments related to Enovis. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from ‘Outperform’ to ‘Underperform’. These ratings offer insights into expectations for the relative performance of Enovis compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock’s future value. Comparing the current and prior price targets provides insight into how analysts’ expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock’s potential future performance.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Enovis’s market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Enovis analyst ratings.
About Enovis
Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy.. The company conducts its operations through two operating segments: Prevention & Recovery (“P&R”) and Reconstructive (“Recon”). It generates majority revenue form Prevention & Recovery segment.
Unraveling the Financial Story of Enovis
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Enovis showcased positive performance, achieving a revenue growth rate of 8.78% as of 30 September, 2023. This reflects a substantial increase in the company’s top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company’s net margin is a standout performer, exceeding industry averages. With an impressive net margin of -0.69%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company’s ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.08%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Enovis’s financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.07%, the company showcases efficient use of assets and strong financial health.
Debt Management: Enovis’s debt-to-equity ratio is below the industry average at 0.14, reflecting a lower dependency on debt financing and a more conservative financial approach.
How Are Analyst Ratings Determined?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Image and article originally from www.benzinga.com. Read the original article here.